PharmaRadar360
PharmaRadar360
Intelligence Layer
🌍·1d agoIndustry

UCB receives positive CHMP opinion for new ZILBRYSQ[®]▼ (zilucoplan) pre-filled pen in EU for adults...

ZILBRYSQ® (zilucoplan) pre-filled pen offers the same complement component 5 (C5) inhibitor as the p...

Publisher

U
UCB

Global

This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.

Read original

In-platform summary, original article off-platform

This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.

Summary excerpt

ZILBRYSQ® (zilucoplan) pre-filled pen offers the same complement component 5 (C5) inhibitor as the p...

Source route

Continue on ucb.com

Leave the platform to read the original full article on the publisher site.

Source: UCB

Scope: Industry

Open original article

Related coverage

More related coverage

UCB·17h ago

UCB Annual General Meeting of Shareholders 2026

UCB Annual General Meeting of Shareholders 2026 | UCB

GSK RSS·5h ago

27 March 2026Bepirovirsen accepted for review by the European Medicines Agency as a potential first-in-class treatment for chronic hepatitis BSubmission supported by statistically significant and clinically meaningful functional cure rates in pivotal PhIII B-Well trials

Pharmaceutical Technology·5h ago

Rocket’s gene therapy Kresladi wins FDA approval in rare immune disease

Pharmaceutical Technology·5h ago

Novartis to acquire Excellergy for $2bn upfront

UCB receives positive CHMP opinion for new ZILBRYSQ[®]▼ (zilucoplan) pre-filled pen in EU for adults... | PharmaRadar360